This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Crohn disease more common in people with hidradenitis suppurativa

Crohn disease more common in people with hidradenitis suppurativa

Pediatric patients with hidradenitis suppurativa (HS) have a higher prevalence of Crohn disease, according to a research letter published online June 14 in JAMA Dermatology.

Nicole Mastacouris, from the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New Hyde Park, New York, and colleagues compared the prevalence of Crohn disease among with and without HS. The analysis included 2,883 patients with HS (aged 12 to 17 years) and 222,186 control patients.

The researchers found that Crohn disease was prevalent in 0.69 percent of patients with HS and 0.17 percent of control patients (unadjusted prevalence ratio, 4.11). Crohn disease prevalence remained higher in patients with HS in the adjusted analysis (adjusted prevalence ratio, 4.90) versus control patients. Similar results were seen among patients aged 15 to 17 years with HS (adjusted prevalence ratio, 4.84) versus those without.

"Findings of this study suggest an association between Crohn disease and HS in pediatric patients," the authors write. "However, the low-absolute prevalence of Crohn disease in this group is reassuring and should be taken into context when counseling ."

One author disclosed to , including AbbVie, which supported the study.

More information: Nicole Mastacouris et al, Prevalence of Crohn Disease Among Pediatric Patients With Hidradenitis Suppurativa, JAMA Dermatology (2023). DOI: 10.1001/jamadermatol.2023.1585

Journal information: JAMA Dermatology

Copyright © 2023 HealthDay. All rights reserved.

Citation: Crohn disease more common in people with hidradenitis suppurativa (2023, June 15) retrieved 30 November 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Upadacitinib superior to placebo in moderate-to-severe Crohn disease


Feedback to editors